SyntekaBio Licenses Out Five AI-Designed Multispecific Antibodies to Panolos

SyntekaBio, an AI-driven drug discovery company, announced on the 15th that it has entered into a license-out agreement with Panolos Biosciences, a company specializing in multispecific antibody-based drug development, covering five antibody candidate assets for the treatment of cancer and immune-related diseases.

The deal represents a concrete outcome of the multispecific antibody co-development memorandum of understanding(MOU) signed by the two companies in early December and marks the first case in which SyntekaBio‘s AI-based antibody development platform has advanced into full-scale commercialization.

The licensed assets consist of five antibody candidates selected from a broader pool of oncology and immunology candidates discovered through SyntekaBio’s AI-driven Asset Program. These candidates were rapidly identified, designed, and optimized using the company‘s antibody discovery platform, Ab-ARS™, and are regarded as next-generation antibody assets that overcome the limitations of conventional antibody discovery approaches.

Under the terms of the agreement, SyntekaBio will transfer the technical data and related intellectual assets for the five candidates, while Panolos Biosciences will proceed with further development and clinical programs for those candidates it elects to in-license.

Panolos Biosciences plans to apply its proprietary αART® (Alpha Antibody Redesign Technology) platform to the acquired candidates to develop next-generation multispecific antibody therapeutics. The αART® platform leverages protein engineering–based structural design to precisely combine and control multiple targets within a single molecule. The company has previously demonstrated the platform’s capabilities through the development of PB203, a triple-target immuno-oncology antibody candidate.

SyntekaBio emphasized that the transaction is particularly meaningful as the first antibody-focused license-out achieved through its Asset Program. The company has been expanding the program across multiple modalities, including small-molecule drugs and antibody therapeutics, and expects the successful execution of this deal to further enhance opportunities for global co-development partnerships and technology exports.

“This agreement is a significant milestone that validates the competitiveness of our AI-based antibody discovery platform through a tangible license-out outcome,” said Jongseon Jung, Chief Executive Officer of SyntekaBio. “We plan to accelerate additional license-out transactions and co-development discussions based on our Asset Program to generate meaningful results in the global market.”

Hye-sung Lim, Chief Executive Officer of Panolos Biosciences, added, “By combining SyntekaBio‘s AI capabilities with our αART®-based multispecific antibody design expertise, we expect to build a pipeline of next-generation antibody therapeutics with high therapeutic value.” He noted that the company will move swiftly to advance manufacturing and in vitro efficacy evaluations of the triple-target candidates to deliver visible development progress.

SOURCE : https://pharm.edaily.co.kr/News/Read?newsId=04326326642399176&mediaCodeNo=257